Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Outset Medical (Nasdaq: OM) reported strong Q2 2025 financial results, with net revenue reaching $31.4 million, up 15% year-over-year. The company's performance was driven by a 25% increase in Tablo console revenue and 11% growth in recurring revenue to $22.5 million.
Key highlights include improved gross margin of 37.8% (38.4% non-GAAP), a 30% reduction in operating expenses, and 60% lower cash usage compared to the previous year. The company secured a significant enterprise agreement providing Tablo access to over 100 facilities, expanding its presence to more than 900 acute and sub-acute sites in the U.S.
Following these results, Outset Medical raised its 2025 revenue guidance to $122-126 million from $115-125 million, maintaining expectations for high-30% non-GAAP gross margin and cash usage below $50 million for the year.
Outset Medical (Nasdaq: OM) has appointed Brittni McGill as its first Chief Nursing Officer, marking a significant addition to its executive team. McGill brings 18 years of nursing and hospital executive experience, previously managing over 1,400 employees at a 350-bed hospital.
In her prior role, McGill demonstrated notable success implementing Outset's Tablo system, achieving a 98% successful treatment rate and reducing central line blood stream infections by 75%. As CNO, she will lead clinical education and support programs for the dialysis nursing community, focusing on strategic outreach and clinical program innovation.
Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis technology, has scheduled its Q2 2025 financial results announcement for August 6, 2025 after market close.
The company will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day, featuring Chair and CEO Leslie Trigg and CFO Renee Gaeta. Participants can register online to receive dial-in details, and a webcast will be available on the company's investor relations website.
Outset Medical (Nasdaq: OM) has appointed healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee, replacing Dale E. Jones who has stepped down. O'Boyle brings over 20 years of healthcare leadership experience, having served as CFO of several public companies and as a board director for 6 public medical device companies.
O'Boyle's extensive board experience includes positions at Nevro Corp., GenMark Diagnostics (as Chairman), Sientra, Wright Medical Group, Zeltiq Aesthetics, and Durata Therapeutics. He previously served as CFO of Advanced Biohealing and NuVasive, and currently serves on the board of Carlsmed, a private spine surgery solutions company.
Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its upcoming participation in the RBC Capital Markets Global Health Care conference. The company's management team will present on Tuesday, May 20, 2025, at 10:30 a.m. Eastern time. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.outsetmedical.com.
- Tablo console revenue grew 23% from Q4
- Recurring revenue from consumables and services increased 20% to $22.7 million
- Gross margin expanded to 37.2% (37.6% non-GAAP)
- Operating expenses decreased 39% to $27.5 million
- Net loss improved to $25.8 million ($3.66 per share)
- Cash position of $192 million as of March 31, 2025
Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis technology, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025, after market close.
The company will host a conference call at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on the same day, featuring Chair and CEO Leslie Trigg and CFO Nabeel Ahmed to discuss the financial and operating results. Interested participants can register online to receive dial-in details and a unique pin for the call.
A live and archived webcast will be available on the company's investor relations website.
Outset Medical (Nasdaq: OM) has announced a one-for-fifteen reverse stock split effective March 20, 2025. The medical technology company's common stock will continue trading under the OM symbol on Nasdaq with a new CUSIP number 690145206.
The reverse split, approved by stockholders on March 5, 2025, will reduce outstanding shares from approximately 265 million to 17 million. The split will not alter stockholders' ownership percentages, except for fractional shares which will be paid in cash. The number of authorized shares and par value per share remain unchanged.
The split will proportionally affect shares available under equity incentive plans, stock options, warrants, and restricted stock units. Equiniti Trust Company will manage the process, with registered stockholders' shares automatically converted to book-entry form. Stockholders with shares in 'street name' will have positions automatically adjusted through their brokers.